Literature DB >> 27309633

Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs.

Kathrine Ekström1,2, Morten Dalsgaard3, Kasper Iversen1, Ulrik Pedersen-Bjergaard1, Niels Vejlstrup3, Sarah Seberg Diemar1,2, Manja Idorn4, Birger Thorsteinsson1,2, Thomas Engstrøm3.   

Abstract

OBJECTIVES: Acute STEMI is routinely treated by acute PCI. This treatment may itself damage the tissue (reperfusion injury). Conditioning with GLP-1 analogs has been shown to reduce reperfusion injury. Likewise, ischemic postconditioning provides cardioprotection following STEMI. We tested if combined conditioning with the GLP-1 analog liraglutide and ischemic postconditioning offered additive cardioprotective effect after reperfusion of 45 min coronary occlusion of left anterior descending artery (LAD).
DESIGN: Fifty-eight non-diabetic female Danish Landrace pigs (60 ± 10kg) were randomly assigned to four groups. Myocardial infarction (MI) was induced by occluding the LAD for 45 min. Group 1 (n = 14) was treated with i.v. liraglutide after 15 min of ischemia. Group 2 (n = 17) received liraglutide treatment concomitant with ischemic postconditioning, after 45 min of ischemia. Group 3 (n = 15) recieved ischemic postconditioning and group 4 (n = 12) was kept as controls.
RESULTS: No intergroup differences in relative infarct size were detected (overall mean 57 ± 3%; p = 0.68). Overall mortality was 34% (CI 25-41%) including 26% post-intervention, with no intergroup differences (p = 0.99). Occurrence of ventricular fibrillation (VF) was 59% (CI 25-80%) including 39% postintervention with no intergroup differences (p = 0.65).
CONCLUSIONS: In our closed-chest pig-model, we were unable to detect any cardioprotective effect of liraglutide or ischemic postconditioning either alone or combined.

Entities:  

Keywords:  Cardioprotection; ischemia-reperfusion injury; ischemic postconditioning; liraglutide

Mesh:

Substances:

Year:  2016        PMID: 27309633     DOI: 10.1080/14017431.2016.1197417

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  5 in total

Review 1.  Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection.

Authors:  Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2018-08-17       Impact factor: 17.165

2.  Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?

Authors:  Maaike Te Lintel Hekkert; Gary Newton; Dirk J Duncker; Michael D Schneider; Kathryn Chapman; Rehan Aqil; Robert Downham; Robert Yan; Daphne Merkus; Gavin Whitlock; Charlotte A L Lane; Darren Cawkill; Trevor Perrior
Journal:  Basic Res Cardiol       Date:  2021-05-20       Impact factor: 17.165

3.  Glucagon-Like Peptide 1 Receptor Activation Augments Cardiac Output and Improves Cardiac Efficiency in Obese Swine After Myocardial Infarction.

Authors:  Daniel J Sassoon; Johnathan D Tune; Kieren J Mather; Jillian N Noblet; Mackenzie A Eagleson; Abass M Conteh; Joshua T Sturek; Adam G Goodwill
Journal:  Diabetes       Date:  2017-05-08       Impact factor: 9.461

Review 4.  Evaluating Novel Targets of Ischemia Reperfusion Injury in Pig Models.

Authors:  Andrea Baehr; Nikolai Klymiuk; Christian Kupatt
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

5.  Liraglutide preconditioning attenuates myocardial ischemia/ reperfusion injury via homer1 activation.

Authors:  Xiangrong Cui; Hongping Liang; Chonghua Hao; Xuan Jing
Journal:  Aging (Albany NY)       Date:  2021-02-01       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.